@article{Celsa:2026:10.1016/j.jhepr.2025.101685,
author = {Celsa, C and Pressiani, T and Nishida, N and Mohamad, Chamseddine S and Arvind, A and Li, M and Fortuny, M and Ben, Khaled N and Iavarone, M and Toyoda, H and Giovanni, Rapposelli I and Casadei-Gardini, A and Vivaldi, C and Ulahannan, S and Andanamala, H and Scheiner, B and Pinter, M and Orlandi, E and Fulgenzi, CAM and Manfredi, GF and Lombardi, P and DAlessio, A and Stefanini, B and Villani, R and Romana, Ponziani F and Stella, L and Carminati, O and Dalia, Ricci A and Gonzalez, M and Sparacino, A and Di, Maria G and Vaccaro, M and Cabibbo, G and Cammà, C and Reig, M and Kelley, RK and Singal, AG and Kaseb, AO and Kudo, M and Rimassa, L and Pinato, D},
doi = {10.1016/j.jhepr.2025.101685},
journal = {JHEP Reports},
title = {Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study},
url = {http://dx.doi.org/10.1016/j.jhepr.2025.101685},
volume = {8},
year = {2026}
}

Download

TY  - JOUR
AB  - Background & AimsDurvalumab plus tremelimumab (STRIDE) has emerged as a first-line systemic treatment option for unresectable hepatocellular carcinoma (HCC). This international multicentre study aimed to evaluate the efficacy and tolerability of STRIDE or durvalumab monotherapy in routine clinical practice, comparing outcomes between patients within and outside key eligibility criteria for the HIMALAYA trial.MethodsFrom a database of 1,423 patients with advanced/unresectable HCC treated with immunotherapy across 35 centres, we analysed 233 patients receiving STRIDE or durvalumab monotherapy. Patients were categorized as HIMALAYA-IN or HIMALAYA-OUT based on key trial eligibility criteria (no prior systemic therapy, ECOG-PS 0–1, Child-Pugh class A, no Vp4 thrombosis). Baseline characteristics were assessed for overall survival (OS) and hepatic decompensation using a multivariable Cox model and competing-risk analysis, respectively. Objective response rates and treatment-related adverse events were recorded.ResultsOf the 233 patients, 123 (53%) were HIMALAYA-IN and 110 (47%) were HIMALAYA-OUT. STRIDE was given in 95% of HIMALAYA-IN patients. After median follow-up of 6.0 months, median OS was 20.4 months (95% CI 11.7-NR) in the overall population. HIMALAYA-IN patients achieved significantly longer OS than HIMALAYA-OUT patients (23.0 vs. 12.2 months; hazard ratio 0.61; 95% CI 0.39-0.96; p = 0.03). Macrovascular invasion and hepatic decompensation were independent negative prognostic factors in the whole cohort. Hepatic decompensation occurred in 10.5% of patients within 12 months from treatment start. Objective response rate was 23.7% and 17.8% of HIMALAYA-IN and -OUT patients, respectively. Patients achieving disease control (whole cohort: 59.4%) demonstrated 24-month OS of 58.2% in HIMALAYA-IN and 44.8% in HIMALAYA-OUT groups. Grade 3-4 treatment-related adverse events occurred in 16.3% of patients.ConclusionsSTRIDE shows reproducible effectiveness and an ac
AU  - Celsa,C
AU  - Pressiani,T
AU  - Nishida,N
AU  - Mohamad,Chamseddine S
AU  - Arvind,A
AU  - Li,M
AU  - Fortuny,M
AU  - Ben,Khaled N
AU  - Iavarone,M
AU  - Toyoda,H
AU  - Giovanni,Rapposelli I
AU  - Casadei-Gardini,A
AU  - Vivaldi,C
AU  - Ulahannan,S
AU  - Andanamala,H
AU  - Scheiner,B
AU  - Pinter,M
AU  - Orlandi,E
AU  - Fulgenzi,CAM
AU  - Manfredi,GF
AU  - Lombardi,P
AU  - DAlessio,A
AU  - Stefanini,B
AU  - Villani,R
AU  - Romana,Ponziani F
AU  - Stella,L
AU  - Carminati,O
AU  - Dalia,Ricci A
AU  - Gonzalez,M
AU  - Sparacino,A
AU  - Di,Maria G
AU  - Vaccaro,M
AU  - Cabibbo,G
AU  - Cammà,C
AU  - Reig,M
AU  - Kelley,RK
AU  - Singal,AG
AU  - Kaseb,AO
AU  - Kudo,M
AU  - Rimassa,L
AU  - Pinato,D
DO  - 10.1016/j.jhepr.2025.101685
PY  - 2026///
SN  - 2589-5559
TI  - Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study
T2  - JHEP Reports
UR  - http://dx.doi.org/10.1016/j.jhepr.2025.101685
VL  - 8
ER  - 

Download